Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
259
datasets available to search
ShareScore release 0.9.0
Dataset results
259 results for “hypertrophic cardiomyopathy”
Optical Trapping Data for the manuscript "Myosin with hypertrophic cardiomyopathy mutation R712L has a reduced working stroke which is rescued by omecamtiv mecarbil"
<p>Optical Trapping Data for the manuscript "Myosin with hypertrophic cardiomyopathy mutation R712L has a reduced working stroke which is rescued by omecamtiv mecarbil"</p>
Data from: The demanding grey zone: sport indices by cardiac magnetic resonance imaging differentiate hypertrophic cardiomyopathy from athlete's heart
Background: We aimed to characterize gender specific left ventricular hypertrophy using a novel, accurate and less time demanding cardiac magnetic resonance (CMR) quantification method to differentiate physiological hypertrophy and hypertrophic cardiomyopathy based on a large population of highly trained athletes and hypertrophic cardiomyopathy patients. Methods and Results: Elite athletes (n=150,>18 training hours/week), HCM patients (n=194) and athletes with hypertrophic cardiomyopathy (n=10) were examined by CMR. CMR based sport indices such as maximal end-diastolic wall thickness to left ventricular end-diastolic volume index ratio (EDWT/LVEDVi) and left ventricular mass to left ventricular end-diastolic volume ratio (LVM/LVEDV) were calculated, established using both conventional and threshold-based quantification method. Whereas 47.5% of male athletes, only 4.1% of female athletes were in the grey zone of hypertrophy (EDWT 13-16mm). EDWT/LVEDVi discriminated between physiological and pathological left ventricular hypertrophy with excellent diagnostic accuracy (AUCCQ:0.998, AUCTQ:0.999). Cut-off value for LVM/LVEDVCQ<0.82 mm×m2/ml and for EDWT/LVEDViTQ<1.27 discriminated between physiological and pathological left ventricular hypertrophy with a sensitivity of 77.8% and 89.2%, a specificity of 86.7% and 91.3%, respectively. LVM/LVEDV evaluated using threshold-based quantification performed significantly better than conventional quantification even in the male subgroup with EDWT between 13-16mm (p<0.001). Conclusions: Almost 50% of male highly trained athletes can reach EDWT of 13 mm. CMR based sport indices provide an important tool to distinguish hypertrophic cardiomyopathy from athlete's heart, especially in highly trained athletes in the grey zone of hypertrophy.
The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study
ClinicalTrials.gov study NCT01160536. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
ClinicalTrials.gov study NCT00035386. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT01447654. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
ClinicalTrials.gov study NCT00001965. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT01198899. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
ClinicalTrials.gov study NCT02590809. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT01631006. IPD Sharing: Not stated. Countries: 1. Publications: 1.
French Hypertrophic Cardiomyopathy Observatory
ClinicalTrials.gov study NCT01091480. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT05366101. IPD Sharing: YES. Countries: 1. Publications: 19.
Renal Denervation in Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT05577208. IPD Sharing: YES. Countries: 1. Publications: 23.
Echocardiography-guided Transthoracic Radio Frequency/Laser Ablation for Ventricular Septum of Hypertrophic Obstructive Cardiomyopathy
ClinicalTrials.gov study NCT02888132. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Correlation Between Myocardial Deformation and Coronary Artery Tortuosity in Patients With Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT04830787. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT05582395. IPD Sharing: YES. Countries: 23. Publications: 4.
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
ClinicalTrials.gov study NCT06412666. IPD Sharing: NO. Countries: 6. Publications: 1.
Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT03259113. IPD Sharing: NO. Countries: 1. Publications: 8.
Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.
ClinicalTrials.gov study NCT02054221. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT06003478. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan
ClinicalTrials.gov study NCT06181617. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.